Founder of Blueprint. I help companies stop sending emails nobody wants to read.
The problem with outbound isn't the message. It's the list. When you know WHO to target and WHY they need you right now, the message writes itself.
I built this system using government databases, public records, and 25 million job posts to find pain signals most companies miss. Predictable Revenue is dead. Data-driven intelligence is what works now.
Your GTM team is buying lists from ZoomInfo, adding "personalization" like mentioning a LinkedIn post, then blasting generic messages about features. Here's what it actually looks like:
The Typical Aspire Pharma SDR Email:
Why this fails: The prospect is an expert. They've seen this template 1,000 times. There's zero indication you understand their specific situation. Delete.
Blueprint flips the approach. Instead of interrupting prospects with pitches, you deliver insights so valuable they'd pay consulting fees to receive them.
Stop: "I see you're hiring compliance people" (job postings - everyone sees this)
Start: "Your trust's oncology patient compliance is 22 percentage points below 3 comparable centers" (NHS Performance Dashboard with specific metrics)
PQS (Pain-Qualified Segment): Reflect their exact situation with such specificity they think "how did you know?" Use government data with dates, record numbers, facility names.
PVP (Permissionless Value Proposition): Deliver immediate value they can use today - analysis already done, deadlines already pulled, patterns already identified - whether they buy or not.
These messages are ordered by quality score (highest first). Each demonstrates either precise understanding of the prospect's situation (PQS) or delivers immediate actionable value (PVP).
Proactive alert to formulary committees that NICE appraisal for improved formulation X completes in 8 weeks, with typical 8-week post-approval shortages - reserve manufacturing capacity now to avoid disruption and prepare formulary recommendations before national shortage hits.
This prevents a costly procurement mistake. The specificity of knowing exact approval dates and your trust's tender timeline proves you did real research. The insight helps them do their job better whether they buy from you or not - that's genuine decision support, not disguised selling.
This play requires internal NICE appraisal pipeline timelines, expected approval windows, and manufacturing capacity allocation data for upcoming formulations.
Combined with public formulary committee schedules to identify timing conflicts. This synthesis is unique to your business.Cross-reference the prospect's tender schedule with NICE approval timelines to identify conflicts where procurement specs will be finalized before improved formulations are approved - locking them into suboptimal options.
You researched their specific tender calendar and identified a real operational problem they likely haven't noticed yet. The timing conflict is verifiable and the question is trivial to answer. Extremely actionable without needing a meeting.
This play requires knowledge of trust procurement schedules combined with internal NICE approval timeline tracking.
The synthesis of their tender calendar with your approval pipeline creates unique timing intelligence.Build readmission cost analysis for specific trusts showing preventable costs linked to formulation tolerability in oncology protocols, with peer trust benchmarking showing better outcomes with improved formulations.
The specific monetary impact tied to their trust is verifiable. Protocol-level granularity shows real analytical work. Peer comparison provides context. Directly addresses their budget management KPI with an easy ask.
This play requires anonymized cost-per-patient and clinical compliance metrics from NHS customers using improved formulations vs standard versions, aggregated by region and trust size with percentile ranges.
Combined with public trust readmission data to create ROI model. This synthesis is proprietary to your business.Alert formulary committees that their Q2 tender for specific therapeutic areas closes before NICE approvals hit for improved formulations - creating an 18-month lock-in to current presentations.
Exact dates make this verifiable and urgent. Prevents a real procurement mistake. Specific therapeutic area identification. Easy ask with genuine job-performance value.
This play requires trust procurement calendar knowledge combined with internal NICE approval pipeline tracking.
Enables better procurement decisions that improve patient access to optimized formulations.Build compliance benchmarking showing preventable readmissions linked to formulation tolerability, with peer comparisons showing better compliance using oral alternatives in specific protocols.
Specific monetary impact the recipient can validate. Protocol-level detail suggests real analysis. Compares to actual peers, not generic averages. Directly addresses cost-containment KPI with easy yes/no question.
This play requires anonymized compliance improvement data from NHS customers, combined with trust readmission cost data and formulary choices for peer benchmarking.
Identifies cost savings and patient outcome improvements through formulary optimization.Map designated specialty centers' rare disease formularies against regional peers to identify improved formulations they've adopted that the recipient hasn't - with patient compliance data showing material outcome improvements.
Specific count (7 formulations) makes it concrete. Tied to their outcomes metrics, not generic benefits. Peer comparison is fair and relevant with low-commitment ask. Helps identify formulary blind spots.
This play requires aggregated adoption rates of improved formulations across 10+ NHS trusts per therapeutic area and region, showing penetration percentage and time-to-adoption percentiles.
Combined with public specialty center designations. Identifies formulary gaps that could improve patient outcomes.Identify trusts whose ophthalmology procurement closes before NICE approves improved formulation for macular degeneration - formulation addresses compliance issues with twice-daily dosing current protocol requires.
Exact dates make this immediately verifiable. Specific therapeutic area and condition. Links to real compliance problem (twice-daily dosing). Easy routing question with genuinely helpful timing alert.
This play requires trust procurement calendar knowledge combined with internal NICE approval timeline tracking and current formulary analysis.
Creates timing intelligence that helps committees avoid procurement mistakes.Identify trusts where oncology patient compliance is significantly below comparable centers, with peer analysis showing the gap correlates with formulation tolerability - peers have adopted oral versions the target hasn't.
Specific 22% gap with monetary impact they can verify. Identifies root cause (formulation choice) not just symptom. Compares to actual peer trusts, not generic benchmarks. Non-threatening routing question.
This play requires anonymized cost-per-patient and clinical compliance metrics from NHS customers, combined with public trust compliance data and internal formulation adoption analysis.
Readmission cost modeling creates monetary impact calculation.Compare designated centers in the same region to identify improved formulations that peer centers have adopted in the past 18 months that the target center is missing - gaps likely explain lower patient satisfaction scores.
Specific count (6 formulations) is concrete. Peer comparison to similar centers is fair. Links to patient satisfaction KPI they track. Non-threatening routing question. Helps identify blind spot in their processes.
This play requires aggregated NHS formulary adoption data across regional trusts combined with patient satisfaction scores by trust.
Regional benchmarking identifies formulary gaps with performance impact.Alert specialty centers that their adoption of optimized rare disease formulations is 18% lower than peer centers in their NHS region - gap likely impacts patient compliance scores and formulary cost-per-outcome metrics.
Specific benchmark comparison showing they analyzed the trust vs peers. 18% gap is measurable and relevant to their KPIs. Focuses on their performance problem, not just selling. Easy routing question, not confrontational. Helps identify blind spot in formulary management.
This play requires aggregated adoption rates of improved formulations across 10+ NHS trusts per therapeutic area and region, showing penetration percentage and time-to-adoption percentiles.
Combined with public specialty center designations from HSS Directory.Analyze oncology outcomes showing 22% lower compliance than peer trusts with similar patient demographics - correlation points to IV-only protocols where peers use better-tolerated oral formulations.
Specific performance gap that matters to their KPIs. Root cause analysis (IV vs oral) is actionable. Peer comparison is fair and verifiable. Non-accusatory framing with easy routing question.
This play requires patient compliance data by trust combined with formulary records showing IV vs oral adoption patterns.
Correlation analysis identifies formulation-driven compliance gaps.Compare formulation adoption across regional specialty centers - target center is 18 percentage points behind on patient-preferred rare disease options, showing up in compliance metrics and potentially CQC ratings.
Specific ranking against actual peers in their region. Links directly to CQC ratings they care about. Actionable - suggests formulary committee isn't aware. Easy yes/no question.
This play requires NHS trust formulary data combined with public CQC ratings correlation analysis.
Regional benchmarking identifies adoption gaps with quality rating impact.Old way: Spray generic messages at job titles. Hope someone replies.
New way: Use public data to find NHS trusts in specific painful situations. Then mirror that situation back to them with evidence.
Why this works: When you lead with "Your trust's oncology compliance is 22% below 3 peer centers" instead of "I see you're expanding rare disease services," you're not another sales email. You're the person who did the homework.
The messages above aren't templates. They're examples of what happens when you combine real data sources with specific situations. Your team can replicate this using the data recipes in each play.
Every play traces back to verifiable data. Here are the sources used in this playbook:
| Source | Key Fields | Used For |
|---|---|---|
| NHS Digital Data Portal | hospital_trust_name, specialty_codes, service_descriptions, pharmacy_contacts | Identifying hospital trusts managing complex specialty populations |
| Rare Disease Dataset (NDRS/NCARDRS) | hospital_trust_identifier, rare_disease_codes, patient_demographics, clinical_outcomes | NHS trusts actively managing rare disease populations |
| NHS Performance Dashboard (Nuffield Trust) | trust_name, quality_metrics, waiting_times, patient_outcomes, specialty_performance | Quality metrics revealing trusts struggling with patient outcomes |
| NHS Commissioning Data Sets (CDS) | secondary_care_provider_name, specialty_code, patient_episodes, treatment_codes | NHS secondary care providers by specialty, patient volume analysis |
| England Rare Diseases Action Plan 2025 | designated_specialist_centers, participating_hospital_trusts, pharmacy_coordinator_contacts | NHS trusts and pharmacies working on rare disease management |
| NHSBSA Prescription Data | dispensing_organization, medicine_code, formulation_type, patient_volume | Prescribing patterns and formulation usage across NHS pharmacies |
| Highly Specialised Services (HSS) Directory | designated_center_name, specialty_code, geography, chief_pharmacist_contact | NHS centers designated to deliver highly specialized services |
| Internal Customer Data | adoption_rates, compliance_metrics, cost_per_patient, formulation_choices | Proprietary benchmarking, ROI analysis, peer adoption comparisons |
| Internal NICE Appraisal Pipeline | approval_timelines, manufacturing_capacity, expected_approval_windows | Supply chain alerts, procurement timing intelligence |